Cancer patients over 65, on multiple medicines, are at higher risk of hospitalization

March 20, 2020

PHILADELPHIA - As adults age, they accumulate a number of medications for chronic conditions. Older patients take anywhere between 5-15 medications per year, which increases the risk that some of the drugs will counteract each other. Older patients also make up the majority of cancer patients, and the majority of cancer deaths. What happens when cancer therapy is added onto an already full plate of medications?

In the largest retrospective population-based study to date, Jefferson researchers showed that hospitalization increase by as much as 114% in patients battling breast, prostate, and lung cancers, when those patients took 15 or more medications prior to chemotherapy treatment. "The comprehensive real-world data we looked at gives us a sense of what's happening today, and offers clues on how we could reduce hospitalizations in older cancer patients," says senior author Grace Lu-Yao, PhD, associate director of Population Science at the Sidney Kimmel Cancer Center (SKCC)--Jefferson Health.

The study was published in the Journal of Geriatric Oncology on March 19th.

"The older patients get, typically the more complex their care becomes - this is especially true when cancer treatment is combined with pre-existing conditions," says co-author Andrew Chapman, DO, co-director of the Senior Adult Oncology Center and chief of Cancer Services at the SKCC.

The researchers identified a pool of 13,959 patients with prostate, lung, and breast cancer from a national database of Medicare cancer patients. They grouped patients by the number of medicines they were on for the 6-months prior to starting intravenous chemotherapy for their cancer. "By looking at hospitalization rates in the 6-months leading up to the start of chemotherapy, we were able to get a baseline, or 'before' data point for these patients, that we could compare against the rates of hospitalization after chemo," said Dr. Lu-Yao.

Drug-drug interactions - where one drug can reduce the effectiveness of another and cause dangerous accumulations of another drug or other effects - are nearly a certainty when people take over eight medicines at once. The researchers saw that the cancer patients studied were starting at a high number of medications already. Lung cancer patients were taking a median of 11 medications, prostate cancer patients were at 10, and those with breast cancer were on a median of 6 therapies.

"Polypharmacy, defined as patients taking 5 or more medications, is a serious problem in patients," says Ginah Nightingale, PharmD, an associate professor in the College of Pharmacy at Thomas Jefferson University, who is an emerging leader in the field of geriatric polypharmacy. "Older patients see multiple specialists, and those specialists rarely coordinate with each other to ensure that the medications are absolutely essential, or weighed against a patient's priorities. So patients end up accumulating more than they absolutely need to take."

The researchers found that lung cancer patients taking between 5-9 medications had a 42% higher rate of hospitalization, those taking 10-14 medications had a 75% increase, and those taking over 15 medications prior to chemotherapy had a 114% higher rate compared to patients taking fewer than five medicines. The researchers saw similar increases in both breast and prostate cancer patients as well.

"The question is whether we can work with patients and their multiple healthcare providers to de-prescribe medicines that might no longer be essential and may interfere with their cancer care," says Dr. Nightingale. "We are in the process of designing a randomized study to test whether we can improve cancer-patient outcomes by reducing the number of medications in the older population of patients."
This project was supported, in part, by the SKCC Cancer Center Support Grant (NCI Award 5P30CA056036-19), and the SKCC Biostatistics Shared Resource (NCI Award 5P30CA056036).

Article Reference: Grace Lu-Yao, Ginah Nightingale, Nikita Nikita, Scott Keithe, Krupa Gandhi, Kristine Swartz, Ralph Zinner, Swapnil Sharma, W.M. Kevin Kelly, Andrew Chapman, "Relationship between polypharmacy and inpatient hospitalization among older adults with cancer treated with intravenous chemotherapy," Journal of Geriatric Oncology, DOI: 10.1016/j.jgo.2020.03.001, 2020.

Media Contact: Edyta Zielinska, 215-955-7359,

Thomas Jefferson University

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to